BioCentury
ARTICLE | Clinical News

CGF166: Phase I/II suspended enrollment

February 1, 2016 8:00 AM UTC

GenVec said Novartis paused enrollment in an open-label, U.S. Phase I/II trial of CGF166 to conduct a safety review based on a recommendation from the trial’s DSMB. GenVec said the trial will continue to collect safety and efficacy data on 9 patients already enrolled. GenVec declined to discuss the DSMB’s specific reason for recommending the pause or the board’s safety criteria for the trial, but hopes the study will restart enrollment within “a few months” and generate data by 2017. ...